Heart Disease Clinical Trials in San Francisco

Showing 181-200 of 283 trials

Use of 3-D Blood Pool Scintigraphy to Guide Left Ventricular Pacing Lead Placement in Patients Requiring Cardiac Resynchronization Therapy

NCT02669290

The purpose of this study is to determine whether multiple gated acquisition (MUGA) guided lead placement improves clinical outcomes for patients needing cardiac resynchronization therapy (CRT) compared to traditional posterolateral left ventricular lead placement.

Heart FailureLeft Ventricular DysfunctionCardiac Resynchronization Therapy

University of California, San Francisco60 participantsStarted Jan 2007

San Francisco, California, United States

COMPLETEDPhase 3< 1 mile

A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome

NCT00658515

This study will evaluate the potential of RO4607381 to reduce cardiovascular morbidity and mortality in stable coronary heart disease patients with recent Acute Coronary Syndrome (ACS) and evaluate the long term safety profile of the drug. Eligible patients in stable condition will be randomized to receive either RO4607381 600mg po or placebo po, daily, together with a background of standard medication for ACS (including aspirin, antihypertensives and statins). The anticipated time on study treatment is 2+ years, and the target sample size is 15,600 individuals.

Coronary Heart Disease

Hoffmann-La Roche15,871 participantsStarted Apr 2008

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Birmingham, Alabama, United States +1086 more locations

Use of 3-D Blood Pool Scintigraphy to Guide Left Ventricular Pacing Lead Placement in Patients Requiring Cardiac Resynchronization Therapy

A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome

Heart Disease Trials in Other Cities

HW006 LATERAL Thoracotomy

Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis

Bococizumab HIV Evaluation (B-HIVE) Study

DF4 Connector System Post-Approval Study

IMPROVE HF: Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting

Decisional Quality for Patients With Coronary Artery Disease

Evaluation of Cardiac Compass With OptiVol in the Early Detection of Decompensation Events for Heart Failure

CANVAS - CANagliflozin cardioVascular Assessment Study

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Model 4965 Post-Approval Study

Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

Same Day Discharge (SDD) After Implantable Cardioverter Defibrillator (ICD) Implant

The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL)

Detect Fluid Early From Intra-thoracic Impedance Monitoring

Personalized Risk Evaluation and Diagnosis (Using Corus CAD or ASGES) in the Coronary Tree

Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)

Heart Outcomes Prevention and Evaluation 4

Other Conditions in San Francisco